Advertisement

Approach and Management of Cervical Cancer

  • Alvaro Henrique Ingles Garces
  • Andreia Cristina de Melo
  • Eduardo Paulino
  • Angélica Nogueira-Rodrigues
  • Rachele Grazziotin
  • Márcio Lemberg Reisner
  • Mariane Sousa Fontes Dias
  • Gustavo Guitmann
  • Gustavo Iglesias
  • Carlos Gil Ferreira
Chapter

Abstract

Cervical cancer (CC) represents the third most commonly diagnosed cancer and the fourth cause of cancer death in women worldwide [GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012 international agency for research on cancer; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 Dec 2017, 2012]. In 2012, across the world, 528,000 new cases were diagnosed with 266,000 deaths, with 85% of the cases occurring in developing countries (GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012 international agency for research on cancer; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 Dec 2017, 2012; Mathers C, Boerma T, Ma Fat D: The global burden of disease: 2004 update. World Health Organization, Geneva, Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 27 Dec 2017, 2008; Kamangar F, Dores GM, Anderson WF: J Clin Oncol 24:2137–2150, 2006). In the United States, it is the third most common gynaecologic cancer diagnosed and cause of death among gynaecologic cancers (Siegel R, Naishadham D, Jemal A: CA Cancer J Clin 63:11, 2013). Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7% of CCs.

Keywords

Cervical cancer Chemotherapy Radiotherapy 

References

  1. 1.
    GLOBOCAN (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012 international agency for research on cancer; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 Dec 2017
  2. 2.
    Mathers C, Boerma T, Ma Fat D (2008) The global burden of disease: 2004 update. World Health Organization, Geneva, Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 27 Dec 2017
  3. 3.
    Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150CrossRefGoogle Scholar
  4. 4.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11CrossRefGoogle Scholar
  5. 5.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12CrossRefGoogle Scholar
  6. 6.
    World Health Organization (2007) Cervical cancer, human papillomavirus (HPV), and HPV vaccines – key points for policy-makers and health professionals. http://www.who.int
  7. 7.
    Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318(7188):904CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Shaw M, Galobardes B, Lawlor DA, Lynch J, Wheeler B, Davey Smith G (2007) The handbook of inequality and socioeconomic position: concepts and measures. The Policy Press, BristolCrossRefGoogle Scholar
  9. 9.
    Vaccarella S, Laversanne M, Ferlay J, Bray F (2017 Nov 15) Cervical cancer in Africa, Latin America and the Caribbean and Asia: regional inequalities and changing trends. Int J Cancer 141(10):1997–2001CrossRefGoogle Scholar
  10. 10.
    Rio de Janeiro (RJ) Instituto Nacional do Câncer Brasil. Estimativa 2012 Incidência do Câncer no Brasil. Available at: www.inca.gov.br/estimativa/2018. Accessed 25 Mar 2018
  11. 11.
    Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132(10):810CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J et al (2001) Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer 92(12):2999CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    International Collaboration of Epidemiological Studies of Cervical Cancer Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097Google Scholar
  14. 14.
    Bermudez A, Bhatla N, Leung E (2015) Cancer of the cervix uteri. Int J Gynaecol Obstet 131(Suppl 2):S88–S95CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH et al (2005) Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 23(36):9329–9337CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J (2003) Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 91(1):59–66CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hricak H, Yu KK (1996) Radiology in invasive cervical cancer. AJR Am J Roentgenol 167(5):1101–1108CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Subak LL, Hricak H, Powell CB, Azizi L, Stern JL (1995) Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 86(1):43–50CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Grigsby PW, Siegel BA, Dehdashti F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19(17):3745–3749CrossRefGoogle Scholar
  20. 20.
    Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F (1999) Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 17(1):41–45CrossRefGoogle Scholar
  21. 21.
    Hertel H, Kohler C, Elhawary T, Michels W, Possover M, Schneider A (2002) Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer. Gynecol Oncol 87(1):46–51CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL et al (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117(9):1928–1934CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    van de Lande J, Torrenga B, Raijmakers PG, Hoekstra OS, van Baal MW, Brolmann HA et al (2007) Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 106(3):604–613CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Andikyan V, Khoury-Collado F, Denesopolis J, Park KJ, Hussein YR, Brown CL et al (2014) Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough? Int J Gynecol Cancer 24(1):113–117CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cormier B, Diaz JP, Shih K, Sampson RM, Sonoda Y, Park KJ et al (2011) Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol 122(2):275–280CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lecuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Darai E et al (2011) Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol 29(13):1686–1691CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Altgassen C, Hertel H, Brandstadt A, Kohler C, Durst M, Schneider A et al (2008) Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 26(18):2943–2951CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bats AS, Mathevet P, Buenerd A, Orliaguet I, Mery E, Zerdoud S et al (2013) The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol 20(2):413–422CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cibula D, Abu-Rustum NR, Dusek L, Slama J, Zikan M, Zaal A et al (2012) Bilateral ultrastaging of sentinel lymph node in cervical cancer: lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol 127(3):462–466CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cibula D, Abu-Rustum NR, Dusek L, Zikan M, Zaal A, Sevcik L et al (2012) Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol 124(3):496–501CrossRefGoogle Scholar
  31. 31.
    Eiriksson LR, Covens A (2012) Sentinel lymph node mapping in cervical cancer: the future? BJOG 119(2):129–133CrossRefGoogle Scholar
  32. 32.
    Wu Y, Li Z, Wu H, Yu J (2013) Sentinel lymph node biopsy in cervical cancer: a meta-analysis. Mol Clin Oncol 1(6):1025–1030CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kadkhodayan S, Hasanzadeh M, Treglia G, Azad A, Yousefi Z, Zarifmahmoudi L et al (2015) Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. Eur J Surg Oncol 41(1):1–20CrossRefGoogle Scholar
  34. 34.
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papilloma- virus and cervical cancer. Lancet 370(9590):89CrossRefGoogle Scholar
  35. 35.
    Wolf JK, Ramirez PT (2001) The molecular biology of cervical cancer. Cancer Investig 19:621–629CrossRefGoogle Scholar
  36. 36.
    zur Hausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Phys 111:581–587CrossRefGoogle Scholar
  37. 37.
    Doorbar J (2005) The papillomavirus life cycle. J Clin Virol 32(suppl 1):S7–S15CrossRefGoogle Scholar
  38. 38.
    Scheuer ME, Tortolero-Luna G, Adler-Storthz K (2005) Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer 15:727–746CrossRefGoogle Scholar
  39. 39.
    Martin CM, Astbury K, O’Leary JJ (2006) Molecular profiling of cervical neoplasia. Expert Rev Mol Diagn 6(2):217–229CrossRefGoogle Scholar
  40. 40.
    Santin AD, Sill MW, McMeekin DS, Leitao MM, Jr Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH (2011) Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 122:495–500CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhang HS, Wang RJ, Fu QF, Gao S, Sun BT, Sun H, Ma QJ (2014) Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer. Asian Pac J Cancer Prev 15(24):10905–10909CrossRefGoogle Scholar
  42. 42.
    Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M (2002) p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26(11):1389–1399CrossRefGoogle Scholar
  43. 43.
    Lee JS, Kim HS, Park JT (2003) Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal Quant Cytol Histol 25:11–303Google Scholar
  44. 44.
    Jansen-Dürr P (1996) How viral oncogenes make the cell cycle. Trends Genet 12(7):270–275. ReviewCrossRefGoogle Scholar
  45. 45.
    Cerciello F, Riesterer O, Sherweif M, Odermatt B, Ciernik IF (2007) Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecol Oncol 106(2):9–394CrossRefGoogle Scholar
  46. 46.
    Fuchs I, Vorsteher N, Bühler H (2007) The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 27(2):63–959Google Scholar
  47. 47.
    Arias PH, Joste N, Chavez A (2008) Absence of epidermal growth receptor mutations in cervical cancer. Int J Gynecol Cancer 18:54–749Google Scholar
  48. 48.
    Marzano R, Corrado G, Merola R (2004) Analysis of chromosomes 3, 7, X and the EGFR gene inuterine cervical cancer progression. Eur J Cancer 40:9–1624CrossRefGoogle Scholar
  49. 49.
    Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD (2003) Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 91(1):231–240CrossRefGoogle Scholar
  50. 50.
    Contreras PA, De la Cruz HE, Martínez RI, Dueñas GA, Lizano M (2009) E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (AKT/PI3K) signaling pathway. Virology 383:78–85CrossRefGoogle Scholar
  51. 51.
    Charette ST, McCance DJ (2007) The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an AKT-dependent manner. Oncogene 52:7386–7390CrossRefGoogle Scholar
  52. 52.
    Bertelsen BI, Steine SJ, Sandvei R (2006) Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PI3KCA amplification and AKT phosphorylation. Int J Cancer 118:1877–1883CrossRefGoogle Scholar
  53. 53.
    Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, Cheung AY, Chung TK, Wong YF (2004) Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 93(3):621–627CrossRefGoogle Scholar
  54. 54.
    Janku F, Wheler J, Westin S et al (2012 Mar 10) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777–782CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Chen YJ (2007) Targetes mTOR in human gynecological cancers. J Cancer Mol 3(4):6–101Google Scholar
  56. 56.
    Fothergill T, McMillan NA (2006) Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 352(2):319–328CrossRefGoogle Scholar
  57. 57.
    Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410. ReviewCrossRefGoogle Scholar
  58. 58.
    Bodily JM, Mehta KP, Laimins LA (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediatedtranscriptional binding of histone deacetylases. Cancer Res 71:1187–1195CrossRefGoogle Scholar
  59. 59.
    Cheng WF, Chen CA, Lee CN (1999) Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93:5–761Google Scholar
  60. 60.
    Richart RM (1973) Cervical intraepithelial neoplasia. In: Pathology annual, vol 8. Appleton-Century-Crofts, East Norwalk, p 301Google Scholar
  61. 61.
    Crum CP (2003) Should the Bethesda system terminology be used in diagnostic surgical pathology?: Point. Int J Gynecol Pathol 22:5CrossRefGoogle Scholar
  62. 62.
    Schneider V (2003) Should the Bethesda system terminology be used in diagnostic surgical pathology?: Counterpoint. Int J Gynecol Pathol 22:13CrossRefGoogle Scholar
  63. 63.
    DeVitaJr VT, Hellman S, Rosenberg SA (2011) Cancer – principles & practice of oncology, vol 1/1, 9th edn. Lippincott Williams & Wilkins, BaltimoreGoogle Scholar
  64. 64.
    Manos MM, Kinney WK, Hurley LB et al (1999) Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281:1605CrossRefGoogle Scholar
  65. 65.
    Ries LAG, Melbert D, Krapcho M et al (2007) SEER cancer statistics review, 1975–2004. National Cancer Institute, BethesdaGoogle Scholar
  66. 66.
    Eifel PJ, Burke TW, Morris M, Smith TL (1995) Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59:38CrossRefGoogle Scholar
  67. 67.
    Smith HO, Tiffany MF, Qualls CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol Oncol 78:97CrossRefGoogle Scholar
  68. 68.
    Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, Scully RE, Silva E, Sobin LH, Tavassoli FJ, Travis WD, Woodruff JM (1997) Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 121:34PubMedGoogle Scholar
  69. 69.
    Villella JA, Bogner PN, Jani-Sait SN, Jani-Sait SN, Block AM, Lele S (2005) Rhabdomyosarcoma of the cervix in sisters with review of the literature. Gynecol Oncol 99:742CrossRefGoogle Scholar
  70. 70.
    Kendrick JE 4th, Straughn JM Jr (2005) Two cases of non-Hodgkin’s lymphoma presenting as primary gynecologic malignancies. Gynecol Oncol 98:490CrossRefGoogle Scholar
  71. 71.
    Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK (2005) Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol 99:348CrossRefGoogle Scholar
  72. 72.
    Azodi M, Chambers SK, Rutherford TJ, Kohorn EI, Schwartz PE, Chambers JT (1999) Adenocarcinoma in situ of the cervix: management and outcome. Gynecol Oncol 73:348CrossRefGoogle Scholar
  73. 73.
    Kostopoulou E, Keating JT, Crum CP (2001) Pathology. In: Eifel PJ, Levenback C (eds) Cancer of the female lower genital tract. B C Decker, Inc, London, p 9Google Scholar
  74. 74.
    Bean SM, Kurtycz DFI, Colgan TJ (2011) Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix. J Lower Genital Tract Dis 15:146–157CrossRefGoogle Scholar
  75. 75.
    Kristensen GB, Abeler VM, Risberg B et al (1999) Tumor size, depth of invasion and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 74:245–251CrossRefGoogle Scholar
  76. 76.
    Young RH, Clement PB (2002) Endocervical adenocarcinoma and its variants: their mor- phology and differential diagnosis. Histopathology 41:185–207CrossRefGoogle Scholar
  77. 77.
    Gien LT, Beauchemin MC, Thomas G (2010) Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116:140–146CrossRefGoogle Scholar
  78. 78.
    Pirog EC, Kleter B, Olgac S et al (2000) Prevalence of human papillomavirus DNA in differ- ent histological subtypes of cervical adenocarcinoma. Am J Pathol 157:1055–1062CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Barakat RR, Berchuck A, Markman M, Randall ME (2013) Principles and practice of gyne- cologic oncology, 6th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  80. 80.
    An HJ, Kim KR, Kim IS et al (2005) Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol 18:528–534CrossRefGoogle Scholar
  81. 81.
    Wang SS, Sherman ME, Silverberg SG, Carreon JD, Lacey JV Jr, Zaino R, Kurman RJ, Hildesheim A (2006) Pathological characteristics of cervical adenocarcinoma in a multi- center U.S.-based study. Gynecol Oncol 103:541–546CrossRefGoogle Scholar
  82. 82.
    Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ (2004) Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 93:27CrossRefGoogle Scholar
  83. 83.
    Landoni F, Maneo A, Colombo A, Placa F, Favini G, Ferri L, Mangioni C (1997) Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350(9077):535–540CrossRefGoogle Scholar
  84. 84.
    Elliott P, Coppleson M, Rusell P, Liouros P, Carter J, Macleod C, Jones M (2000) Early invasive (FIGO stage IA) carcinoma of the cervix: a clinicopathologic study of 476 cases. Int J Gynecol Cancer 10(1):42–45CrossRefGoogle Scholar
  85. 85.
    Morris M, Mitchell MF, Silva EG, Copeland LJ, Gershenson DM (1993) Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. Gynecol Oncol 51(2):193–196CrossRefGoogle Scholar
  86. 86.
    Piver MS, Rutledge F, Smith JP (1994) Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44(2):265–272Google Scholar
  87. 87.
    Querleu D, Morrow CP, Cibula D, Abu-Rustum NR, Benedetti-Panici P, Köhler C, Raspagliesi F (2011) New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. Gynecol Oncol 122(2):264–268CrossRefGoogle Scholar
  88. 88.
    Maiman MA, Fruchter RG, DiMaio TM, Boyce JG (1998) Superficially invasive squamous cell carcinoma of the cervix. Obstet Gynecol 72(4):399–403Google Scholar
  89. 89.
    Dargent D, Martin X, Sacchetoni A, Mathevet P (2000) Laparoscopic vaginal radical trach- electomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 88(8):1877–1882CrossRefGoogle Scholar
  90. 90.
    Mangler M, Lanowska M, Köhler C, Vercellino F, Schneider A, Speiser D (2014) Pattern of cancer recurrence in 320 patients after radical vaginal trachelectomy. Int J Gynecol Cancer 24(1):130–134CrossRefGoogle Scholar
  91. 91.
    Kolomainen DF, Bradley RJ, Larsen-Disney P, Shepherd JH (2013) Radical vaginal trachelectomy at 16 weeks’ gestation: a case report. Gynecol Oncol Case Rep 14(5):28–30CrossRefGoogle Scholar
  92. 92.
    Lanowska M, Mangler M, Speiser D, Bockholdt C, Schneider A, Köhler C, Vasiljeva J, Al-Hakeem M, Vercellino GF (2014) Radical vaginal trachelectomy after laparoscopic staging and neoadjuvant chemotherapy in women with early-stage cervical cancer over 2 cm: oncologic, fertility, and neonatal outcome in a series of 20 patients. Int J Gynecol Cancer 24(3):586–593CrossRefGoogle Scholar
  93. 93.
    Querleu D (1991) Radical hysterectomies by the Schauta-Amreich and Schauta-Stoeckel techniques assisted by celioscopy. J Gynecol Obstet Biol Reprod (Paris) 20(5):747–748Google Scholar
  94. 94.
    Kucukmetin A, Biliatis I, Naik R, Bryant A (2013) Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer. Cochrane Database Syst Rev 10:CD006651Google Scholar
  95. 95.
    Pergialiotis V, Rodolakis A, Christakis D, Thomakos N, Vlachos G, Antsaklis A (2013) Laparoscopically assisted vaginal radical hysterectomy: systematic review of the literature. J Minim Invasive Gynecol 20(6):745–753CrossRefGoogle Scholar
  96. 96.
    Lowe MP, Chamberlain DH, Kamelle SA, Johnson PR, Tillmanns TD (2009) A multi- institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol 113(2):191–194CrossRefGoogle Scholar
  97. 97.
    GilIbáñez B, Díaz-Feijoo B, Pérez-Benavente A, Puig-Puig O, Franco-Camps S, Centeno C, Xercavins J, Gil-Moreno A (2013) Nerve sparing technique in robotic-assisted radical hysterectomy: results. Int J Med Robot 9(3):339–344CrossRefGoogle Scholar
  98. 98.
    Yim GW, Kim SW, Nam EJ, Kim S, Kim YT (2013) Learning curve analysis of robot-assisted radical hysterectomy for cervical cancer: initial experience at a single institution. J Gynecol Oncol 24(4):303–312CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Tinelli R, Malzoni M, Cosentino F, Perone C, Fusco A, Cicinelli E, Nezhat F (2011) Robotics versus laparoscopic radical hysterectomy with lymphadenectomy in patients with early cervical cancer: a multicenter study. Ann Surg Oncol 18(9):2622–2628CrossRefGoogle Scholar
  100. 100.
    Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ (2006) A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 65(1):169–176CrossRefGoogle Scholar
  101. 101.
    Landoni F, Maneo A, Cormio G, Perego P, Milani F, Caruso O, Mangioni C (2011) Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a propective randomized study. Gynecol Oncol 80(1):3–12CrossRefGoogle Scholar
  102. 102.
    Richard SD, Krivak TC, Castleberry A, Beriwal S, Kelley JL 3rd, Edwards RP, Sukumvanich P (2008) Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol 109(1):43–48CrossRefGoogle Scholar
  103. 103.
    Whitney CW, Sause W, Bundy BN et al (1999) A randomized comparison of fl uorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB- IVA carcinoma of the cervix with negative para-aortic lymph nodes. A gynecologic oncology group and southwest oncology group study. J Clin Oncol 17:1339–1348CrossRefGoogle Scholar
  104. 104.
    Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer. Results of a randomized gynecologic oncology group study. N Engl J Med 340:1144–1153CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized radiation therapy oncology group clinical trial. N Engl Med 340:1137–1143CrossRefGoogle Scholar
  106. 106.
    Finlay MH, Ackerman I, Tirona RG, Hamilton P, Barbera L, Thomas G (2006) Use of CT stimulation for treatment of cervical cancer to assess the adequacy of limph node coverage of conventional pelvic fi elds based on bony landmarks. Int J Radiat Oncol Biol Phys 64:205–209CrossRefGoogle Scholar
  107. 107.
    Lim K, Small W Jr, Portelance L et al (2011) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 79(2):348–355CrossRefGoogle Scholar
  108. 108.
    Wolfson AH, Abdel-Wahab M, Markoe AM et al (1997) A quantitative assessment of standard vs. customized midline shield construction for invasive cervical carcinoma. Int J Radiat Oncol Biol Phys 37:237–242CrossRefGoogle Scholar
  109. 109.
    Rajasooriyar C, Van Dyk S, Lindawati M, Bernshaw D, Kondalsamy-Chennakesavan S, Narayan K (2012) Reviewing the role of parametrial boost in patients with cervical cancer with clinically involved parametria and staged with positron emission tomography. Int J Gynecol Cancer 22(9):1532–1537PubMedGoogle Scholar
  110. 110.
    Vargo JA, Kim H, Choi S, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Comerci JT, Beriwal S (2014) Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys 90:1091–1098CrossRefGoogle Scholar
  111. 111.
    Kim YJ, Kim JY, Yoo SH, Min BJ, Chung KZ, Seo SS, Kang SB, Lim MC, Hwang JH, Yoo HJ, Park SY (2013) High control rate for lymph nodes in cervical cancer treated with high-dose radiotherapy using helical tomotherapy. Technol Cancer Res Treat 12:45–51CrossRefGoogle Scholar
  112. 112.
    Herrera FG, Prior JO (2013) The role of PET/CT in cervical cancer. Front Oncol 3:34CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Gandhi AK, Sharma DN, Rath GK et al (2013) Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys 87(3):542–548CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D’Souza D, Souhami L, Small W Jr, Gaur R, Jhingran A (2013) Hematologic toxicitiy in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 86(1):83–90CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Beriwal S, Gan GN, Heron DE et al (2007) Early clinical outcome with concurrent chemotherapy and extended-field, intensitymodulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 68:166–171CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Renard-Oldrini S, Brunaud C, Huger S, Marchesi V, Tournier-Rangeard L, Bouzid D, Harter V, Peiffert D (2012) Dosimetric comparison between the instensity modulated radiotherapy with fixed field and rapid arc of cervix cancer. Cancer Radiother 16(3):209–214CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Wang W, Meng Q, Hou X et al (2017) Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer. Oncotarget 8(61):102965–102973PubMedPubMedCentralGoogle Scholar
  118. 118.
    Lanciano RM, Martz K, Coia LR, Hanks GE (1991) Tumor and treatment factors improving outcome in stage III-B cervix cancer. Int J Radiat Oncol Biol Phys 1:95–100CrossRefGoogle Scholar
  119. 119.
    Hong JC, Foote J, Broadwater G et al (2017) Data-derived treatment duration goal for cervical cancer: should 8 weeks remain the target in the era of concurrent chemoradiation? JCO Clin Cancer Inform 1:1–15CrossRefGoogle Scholar
  120. 120.
    Dimopoulos JC et al (2009) MRI assessment of cervical cancer for adaptive radiotherapy. Strahlenther Onkol 85(5):282–287CrossRefGoogle Scholar
  121. 121.
    Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD (1994) Low dose rate vc. High dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 28:335–341CrossRefGoogle Scholar
  122. 122.
    Huerta Bahena J, Almendaro SL, Arroyo HC, Trejo MB (2008) Three fraction high dose rate brachytherapy schedule for treatment of locally advanced uterine cervix cancer center: clinical results, emphasis in dosimetric parameters and morbidity. Cancerología 3:105–110Google Scholar
  123. 123.
    Viswanathan AN, Beriwal S, De Los Santos J (2012) The American brachytherapy society treatment recommendations for locally advanced carcinoma of the cervix part II: high dose-rate brachytherapy. Brachytherapy 11(1):47–52CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    ICRU (2016) Report 89, prescribing, recording, and reporting brachytherapy for cancer of the cervix. J Int Commission Radiat Units Meas 13, Pages NPGoogle Scholar
  125. 125.
    Abdel-Wahab et al (2017) Analysis of outcomes using external beam radiotherapy plus high dose rate brachytherapy (4×7 Gy or 2×9 Gy) for cervix cancer in a multi-institution trial, Plenary Session at ASTRO’s 59th Annual Meeting, San DiegoGoogle Scholar
  126. 126.
    Choy D, Wong LC, Sham J, Ngan HYS, Ma HK (1993) Dose tumor response for carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. Gynecol Oncol 49:311–317CrossRefGoogle Scholar
  127. 127.
    Viswanathan AN, Thomadsen B (2012) American Brachytherapy Society Cervical Cancer Recommendations Committee; American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11(1):33–46CrossRefGoogle Scholar
  128. 128.
    Rijkmans EC, Nout RA, Rutten IH (2014) Improved survival of patients with cervical cancer treated with image-guided brachytherapycompared with conventional brachytherapy. Gynecol Oncol 135(2):231–238CrossRefGoogle Scholar
  129. 129.
    Pötter R, Georg P, Dimopoulos J et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Mahmoud O, Kilic S, Khan AJ, Beriwal S, Small W Jr (2017) External beam techniques to boost cervical cancer when brachytherapy is not an option—theories and applications. Ann Transl Med 5(10):207CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN (2013) Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 87(1):111–119CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F (1990) Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 38:352CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Levine DA et al (2010) Principles and practice of gynecologic oncology (ed1). Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  134. 134.
    Choy D, Wong LC, Sham J, Ngan HY, Ma HK (1993) Dose-tumor response of carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. Gynecol Oncol 49(3):311–317CrossRefGoogle Scholar
  135. 135.
    Rydzewska L, Tierney J, Vale CL, Symonds PR (2012) Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 12:CD007406PubMedPubMedCentralGoogle Scholar
  136. 136.
    Peters WA III, Liu PY, Barrett RJ et al (1999) Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervicix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. Gynecol Oncol 72:443CrossRefGoogle Scholar
  137. 137.
    Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemoterapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20:966–972CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration CCCMAC (2010) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 1:CD008285Google Scholar
  139. 139.
    Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol 27:4649–4655CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIb to IVa carcinoma of the cervix. J Clin Oncol 29:1678–1685CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Wang N, Guan QL, Wang K, Zhou X, Gao C, Yang HT et al (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet 283(1):103–108CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the cervix uteri. Int J Gynaecol Obstet 95(Suppl 1):S43, FIGO 26th Annual Report on the Results of Treatment in Gynecological CancerGoogle Scholar
  143. 143.
    Lim MC, Lee HS, Seo SS, Kim MS, Kim JY, Zo JI, Park SY (2010) Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thora- cotomy or video-assisted thoracic surgery. Gynecol Oncol 116:478CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Patel CN, Nazir SA, Khan Z, Gleeson FV, Bradley KM (2011) 18F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol 196:1225CrossRefPubMedPubMedCentralGoogle Scholar
  145. 145.
    Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, Ansquer C, Testard A, Resche I, Bridji B, Kraeber-Bodéré F, Rousseau C (2010) Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 37:1270CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Friedlander M, Grogan M (2002) U.S. Preventative services task force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7:342PubMedPubMedCentralGoogle Scholar
  147. 147.
    Berek JS, Howe C, Lagasse LD, Hacker NF (2005) Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99:153CrossRefPubMedPubMedCentralGoogle Scholar
  148. 148.
    Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W, Kirk ME (1994) Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 52:353CrossRefPubMedPubMedCentralGoogle Scholar
  149. 149.
    Mahé MA, Gérard JP, Dubois JB, Roussel A, Bussières E, Delannes M, Guillemin F, Schmitt T, Dargent D, Guillard Y, Martel P, Richaud P, Cuillière JC, De Ranieri J, Malissard L (1996) Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French Intraoperative Group on 70 patients. Int J Radiat Oncol Biol Phys 34:21CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, Lin JD (1999) Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 181:518CrossRefPubMedPubMedCentralGoogle Scholar
  151. 151.
    Haasbeek CJ, Uitterhoeve AL, van der Velden J, González DG, Stalpers LJ (2008) Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 89:197CrossRefPubMedPubMedCentralGoogle Scholar
  152. 152.
    Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Hsueh S (2004) Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 60:249CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Long HJ 3rd. (2007) Management of metastatic cervical cancer: review of the literature. J Clin Oncol 25:2966CrossRefGoogle Scholar
  154. 154.
    Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115:3166CrossRefGoogle Scholar
  155. 155.
    Garces ÁH, Mora PA, Alves FV, do Carmo CC, Grazziotin R, Fernandes AC, Nogueira-Rodrigues A, de Melo AC (2013) First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute. Int J Gynecol Cancer 23(4):743–748CrossRefGoogle Scholar
  156. 156.
    Lhomme C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B (1999) Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recur- rent squamous cell carcinoma of the cervix. J Clin Oncol 17:3142–3142CrossRefGoogle Scholar
  157. 157.
    Brader KR, Morris M, Levenback C, Levy L, Lucas KR, Gershenson DM (1998) Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol 16:1879CrossRefGoogle Scholar
  158. 158.
    Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113CrossRefPubMedPubMedCentralGoogle Scholar
  159. 159.
    Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV (2005) Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 23:4626CrossRefGoogle Scholar
  160. 160.
    Tanioka M, Katsumata N, Yonemori K, Kouno T, Shimizu C, Tamura K, Ando M, Fujiwara Y (2011) Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol 68:337–342CrossRefGoogle Scholar
  161. 161.
    Tewari KS, Sill M, Long HJ et al (2013) Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 31:abstr 3CrossRefGoogle Scholar
  162. 162.
    Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103):1654CrossRefPubMedPubMedCentralGoogle Scholar
  163. 163.
    Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33(19):2129–2135CrossRefGoogle Scholar
  164. 164.
    Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C et al (2017) Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 35(36):4035CrossRefPubMedPubMedCentralGoogle Scholar
  165. 165.
    Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS (1990) A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a southwest oncology group study. Gynecol Oncol 39:332CrossRefPubMedPubMedCentralGoogle Scholar
  166. 166.
    Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 127:451CrossRefPubMedPubMedCentralGoogle Scholar
  167. 167.
    Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A (2004) Gynecologic oncology group study. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 92:639CrossRefPubMedPubMedCentralGoogle Scholar
  168. 168.
    Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH, Alvarez RD (2001) Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 19:1275CrossRefPubMedPubMedCentralGoogle Scholar
  169. 169.
    Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G (2010) Evaluation of pemetrexed (Alimta, LY231514) as second- line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 21:61CrossRefPubMedPubMedCentralGoogle Scholar
  170. 170.
    Thigpen T (2003) The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 9:425CrossRefPubMedPubMedCentralGoogle Scholar
  171. 171.
    Muderspach LI, Blessing JA, Levenback C, Moore JL Jr (2001) A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81:213CrossRefGoogle Scholar
  172. 172.
    Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD (2009) Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 27:1069–1074CrossRefPubMedPubMedCentralGoogle Scholar
  173. 173.
    Monk BJ, Mas Lopwz L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562–3569CrossRefGoogle Scholar
  174. 174.
    Santin AD, Sill MW, McKeekin DS, Leitao MM Jr, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH (2011) Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Glob Open 122(3):495–500Google Scholar
  175. 175.
    Advisory Committee on Immunization Practices (2013) Recommended adult immunization schedule: United States, 2013. Ann Intern Med 158:191CrossRefGoogle Scholar
  176. 176.
    Massad LS, Schneider M, Watts H et al (2001) Correlating papanicolaou smear, colposcopic impression, and biopsy: results from the Women’s interagency HIV study. J Low Genit Tract Dis 5:212PubMedGoogle Scholar
  177. 177.
    Garland SM, Hernandez-Avila M, Wheeler CM, Darragh T, Abulafia O, Salzer E, Muderspach LI, Sidawy M, Melnick S (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928CrossRefGoogle Scholar
  178. 178.
    FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915CrossRefGoogle Scholar
  179. 179.
    Paavonen J, Naud P, Salmerón J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301CrossRefGoogle Scholar
  180. 180.
    National Center for Immunization and Respiratory Diseases (2011) General recommendations on immunization – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60:1Google Scholar
  181. 181.
    Centers for Disease Control and Prevention (CDC) (2013) Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older – United States, 2013. MMWR Surveill Summ 62(Suppl 1):1Google Scholar
  182. 182.
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1PubMedGoogle Scholar
  183. 183.
    Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG et al (2007) Gynecologic Cancer Advisory Group, Garcia F. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57:7CrossRefGoogle Scholar
  184. 184.
    www.who.int/wer. Accessed 8 Dec 2017
  185. 185.
    Giuliano AR, Palefsky JM, Goldstone S et al (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364:401CrossRefPubMedPubMedCentralGoogle Scholar
  186. 186.
    Kim JJ (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10:845CrossRefPubMedPubMedCentralGoogle Scholar
  187. 187.
    Centers for Disease Control and Prevention (CDC) (2011) Recommendations on the use of quadrivalent human papillomavirus vaccine in males-advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011 60:1705Google Scholar
  188. 188.
    Centers for Disease Control and Prevention (CDC) (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:626Google Scholar
  189. 189.
    Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G (2009) A pooled analysis of contin- ued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2:868CrossRefGoogle Scholar
  190. 190.
    Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefGoogle Scholar
  191. 191.
    Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, Taneepanichskul S (2012) Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 15:S29–S34CrossRefGoogle Scholar
  192. 192.
    From the Centers for Disease Control and Prevention (1993) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 269:729CrossRefGoogle Scholar
  193. 193.
    Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R, Gates EJ (1997) Cervical cancer as an AIDS-defining illness. Obstet Gynecol 89:76CrossRefGoogle Scholar
  194. 194.
    Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K (2001) Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 184:682–690CrossRefGoogle Scholar
  195. 195.
    Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, Minkoff H, Hall CB, Bacon MC, Levine AM, Watts DH, Silverberg MJ, Xue X, Melnick SL, Strickler HD (2005) Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 293:1471–1476CrossRefGoogle Scholar
  196. 196.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al (2005) Prophylactic quadri- valent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278CrossRefGoogle Scholar
  197. 197.
    Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, Arrastia CD (1996) Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 87:338CrossRefGoogle Scholar
  198. 198.
    Marnitz S, Schmittel A, Bolbrinker J, Schmidt FP, Fons G, Kalache K, Schneider A, Köhler C (2009) The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum. Fertil Steril 92:e1–e4CrossRefGoogle Scholar
  199. 199.
    Marnitz S, Köhler C, Oppelt P, Schmittel A, Favero G, Hasenbein K, Schneider A, Markman M (2010) Cisplatin application in pregnancy: first in vivo analysis of 7 patients. Oncology 79:72–77CrossRefGoogle Scholar
  200. 200.
    National Comprehensive Cancer Network (2012) Cervical cancer, version 1. Available online http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf
  201. 201.
    Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C (2012) Gynaecological cancers in pregnancy. Lancet 3379:558–569CrossRefGoogle Scholar
  202. 202.
    Morice P, Narducci F, Mathevet P et al (2009) On the behalf of the French Working Group on Gynecological Cancers in Pregnancy, Société Française D’Oncologie Gynécologique (SFOG), Société Française de Chirurgie Pelvienne (SFCP), and the Collège National des Gynécologues Obstétriciens Français (CNGOF). Int J Gynecol Cancer 19:1638–1641CrossRefGoogle Scholar
  203. 203.
    Plante M, Renaud MC, Hoskins IA, Roy M (2005) Vaginal radical trachelectomy: a valuable fertility- preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 98:3–10CrossRefGoogle Scholar
  204. 204.
    Bleyer A, O’Leary M, Barr R, Ries L (eds) (2006) Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767. BethesdaGoogle Scholar
  205. 205.
    Kardakis S (2012) Fertility-preserving surgery in patients with early stage cervical carcinoma. ISRN Oncol. Review of fertility-preserving surgery in cervical carcinomaGoogle Scholar
  206. 206.
    Wright JD, Nathavith Arana R, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ (2010) Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 115:585–590CrossRefGoogle Scholar
  207. 207.
    Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337:a1284CrossRefPubMedPubMedCentralGoogle Scholar
  208. 208.
    Rob L, Charvat M, Robova H, Pluta M, Strnad P, Hrehorcak M, Skapa P (2007) Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer. Int J Gynecol Cancer 17:304–310CrossRefGoogle Scholar
  209. 209.
    Milliken DA, Shepherd JH (2008) Fertility preserving surgery for carcinoma of the cervix. Curr Opin Oncol 20:575–580CrossRefGoogle Scholar
  210. 210.
    Jolley JA, Battista L, Wing DA (2007) Management of pregnancy after radical trachelec tomy: case reports and systematic review of the literature. Am J Perinatol 24:531–539CrossRefPubMedPubMedCentralGoogle Scholar
  211. 211.
    Boss EA, van Golde RJ, Beerendonk CC, Massuger LF (2005) Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 99(Suppl 1):S152–S156. 152CrossRefPubMedPubMedCentralGoogle Scholar
  212. 212.
    Dursun P, Ayhan A, Yanik FB, Kuşçu E (2009) Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma. Eur J Gynaecol Oncol 30:13–15PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alvaro Henrique Ingles Garces
    • 1
  • Andreia Cristina de Melo
    • 2
    • 3
    • 4
  • Eduardo Paulino
    • 5
    • 4
  • Angélica Nogueira-Rodrigues
    • 6
    • 7
    • 4
  • Rachele Grazziotin
    • 8
  • Márcio Lemberg Reisner
    • 8
  • Mariane Sousa Fontes Dias
    • 3
  • Gustavo Guitmann
    • 8
    • 9
    • 10
  • Gustavo Iglesias
    • 8
  • Carlos Gil Ferreira
    • 11
  1. 1.Drug Development Unit and West Wing Clinical Research Centre, The Royal Marsden Foundation TrustSuttonUK
  2. 2.INCA (Brazilian National Cancer Institute)Rio de JaneiroBrazil
  3. 3.Grupo Oncoclínicas do BrasilSão PauloBrazil
  4. 4.Brazilian Group of Gynecologic Oncology, EVA GroupRio de JaneiroBrazil
  5. 5.Department of Gynaecology OncologyBrazilian National Cancer InstituteRio de JaneiroBrazil
  6. 6.Federal University of Minas GeraisBelo HorizonteBrazil
  7. 7.Dom OncologiaDivinópolisBrazil
  8. 8.Brazilian National Cancer InstituteRio de JaneiroBrazil
  9. 9.Department of Gynaecology Oncology, Americas Medical CityRio de JaneiroBrazil
  10. 10.Society Gynecologic OncologyChicagoUSA
  11. 11.President Oncoclínicas InstituteRio de JaneiroBrazil

Personalised recommendations